Company news: KV Pharmaceuticals, Elsevier, Pfizer

Share this article:
KV pharmaceuticals, which declared bankruptcy last week, has chalked up a win in the Georgia courts. A US district court ruled that the Georgia Medicaid program was unfairly sidelining the FDA-approved drug by requiring pre-authorization before patients could receive KV's drug Makena, as reported by Forbes. The court said the pre-approval policy ends up favoring compounded versions of the drug over the FDA-approved one, which is meant to reduce the risk of premature births.

Dutch publisher Elsevier has paired up with Follett Higher Education group. The collaboration will make the publisher's digital Pageburst titles available through Follett's network of academic bookstores, which includes 900 colleges and universities in the US and Canada.

Pfizer continued to power ahead with plans for spinning off its animal health business, Zoetis. The company announced Monday it filed the paperwork with the SEC to pave the way for the unit's IPO. Plans are to put about 20% of the company up for grabs. The IPO is expected early next year.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters